Small-cap stocks rode high atop Thursday's best-performing major index, the Nasdaq, amid a plethora of good news out of the sector.

Penford ( PENX) shares traded furiously to catapult 32.4% on impressive results for the quarter ended May 31. The Englewood, Colo., company, which makes ingredient systems for industrial and food applications, more than doubled its income from last year to $5 million, or 54 cents a share -- double the sole analyst's estimate from Thomson Financial. Shares were changing hands at $25.65.

Among the day's most impressive winners was CryoCor ( CRYO), which booked gains of some 81% after the Food and Drug Administration's advisory panel recommended pre-market-approval of the San Diego company's cryoablation system, a device that treats atrial flutter (abnormal heartbeat). The FDA's ultimate decision should come in August. Shares were up $2.05 to $4.59.

The S&P SmallCap 600 index, of which Penford is a member, climbed 0.4% to 435.27. The Russell 2000 rose 0.3% as one of its components, Comverge ( COMV), surged 14.7% to $32.41 on news it will buy Enerwise Global Technologies for $75.7 million in cash, stock and subordinated convertible bonds.

Comverge, an East Hanover, N.J., energy-equipment company, said it should pull in about $9 million in revenue from Enerwise during the remaining two quarters of 2007, and expects per-share earnings accretion to begin in 2008.

Another Russell 2000 member, Verenium ( VRNM), bounced 12.2% after saying the Department of Energy has allocated it $4.6 million over five years as a member of a biofuels-production-research team led by Oak Ridge National Laboratory. Shares of the Cambridge, Mass., company tacked on 64 cents to $5.89.

But Euro Tech ( CLWT), a water-treatment company based in Hong Kong, slid 16.8% after preliminarily reporting it had halved its fiscal 2006 profit to roughly $361,000 vs. fiscal 2005 on shrinking revenue. Shares gave up 47 cents to $2.30.

Elsewhere, Momenta Pharmaceuticals ( MNTA) was off 6.7% to $10.56 after warning investors that the FDA will probably take longer to review M-Enoxaparin, its generic form of Sanofi-Aventis' ( SNY) blood-clot drug Lovenox, than the previously announced estimate of 18 to 24 months.

Sandoz, a Novartis ( NVS) subsidiary with which Momenta is developing M-Enoxaparin, submitted an abbreviated new-drug application for the compound in August 2005. Sanofi was lately flat at $40.68 as Novartis gained 1%.

More from Investing

10 Stocks Goldman Sachs Thinks Will Crush the S&P 500's Performance in 2019

10 Stocks Goldman Sachs Thinks Will Crush the S&P 500's Performance in 2019

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

3 Warning Signs the Stock Market Could Collapse

3 Warning Signs the Stock Market Could Collapse

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

TheStreet's Top Columnists Take Your Questions on What Stocks to Buy

TheStreet's Top Columnists Take Your Questions on What Stocks to Buy